期刊文献+

基于全国血流感染耐药监测联盟的耐碳青霉烯类革兰阴性菌对替加环素的蒙特卡洛模拟研究 被引量:6

Monte Carlo simulation in evaluating efficacy of tigecycline for carbapenem-resistant Gram-negative bacteria based on BRICS data
原文传递
导出
摘要 目的通过蒙特卡洛模拟评估不同剂量替加环素对碳青霉烯类耐药肠杆菌科细菌(CRE)、碳青霉烯类耐药肺炎克雷伯菌(CRKP)和碳青霉烯类耐药鲍曼不动杆菌(CRAB)的疗效。方法借助全国血流感染细菌耐药监测联盟平台收集2018年1月1日至2019年12月31日626株CRE及317株CRAB,CRE中包括517株CRKP。根据替加环素的三种给药方案(50 mg次/12 h、75 mg次/12 h及100 mg次/12 h)及CRE、CRKP和CRAB的最低抑菌浓度(MIC)分布,基于药代动力学/药效学模型,设置10000次的蒙特卡洛模拟计算,计算在每个MIC值的目标获得概率(PTA)及每种给药方案下的累积响应分数(CFR),设定90%为达标PTA值及目标CFR值。结果对于CRE,当MIC≤0.5 mg/L时,三种给药方案对CRE的模拟结果为PTA均>99%;当MIC=1 mg/L时,75 mg次/12 h和100 mg次/12 h两种方案对应的PTA分别为94.42%和99.65%,50 mg次/12 h给药方案对应的PTA为71.02%;当MIC≥2 mg/L时,三种给药方案对CRE的PTA均不达标。对于CRKP,当MIC≤0.5 mg/L时,三种给药方案对CRKP的模拟结果PTA均>99%;当MIC=1 mg/L时,75 mg次/12 h和100 mg次/12 h两种方案对应的PTA分别为94.27%和99.19%,50 mg次/12 h给药方案未达到目标PTA值;当MIC≥2 mg/L时,三种给药方案对CRKP的PTA均不达标。对于CRAB,当MIC≤0.5 mg/L时,三种给药方案对CRAB的模拟结果PTA均>98%;当MIC=1 mg/L时,75 mg次/12 h和100 mg次/12 h两种方案对应的PTA分别为94.45%和99.00%,50 mg次/12 h给药方案未达到目标PTA值;当MIC≥2 mg/L时,三种给药方案对CRKP的PTA均不达标。替加环素对CRE具有较高的CFR,75 mg次/12 h和100 mg次/12 h替加环素用药方案所对应的CFR分别为92.62%和97.62%。对于CRKP,替加环素50 mg次/12 h、75 mg次/12 h和100 mg次/12 h给药方案下的CFR分别为86.53%、94.40%和97.16%。对于CRAB,三种给药方案对应的CFR分别为41.76%、60.73%和72.21%。结论当MIC≥1 mg/L时,推荐剂量(50 mg次/12 h)的替加环素对CRE、CRKP和CRAB均无效,对于CRE或CRKP,75 mg次/12 h和100 mg次/12 h的剂量可能是更优给药方案。
作者 朱静轩 喻玮 嵇金如 应超群 王培培 刘志盈 杨雪静 曹俊敏 肖永红 Zhu Jingxuan;Yu Wei;Ji Jinru;Ying Chaoqun;Wang Peipei;Liu Zhiying;Yang Xuejing;Cao Junmin;Xiao Yonghong(The First Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310006,China;State Key Laboratory of Infectious Disease Diagnosis and Treatment,the First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310003,China;Laboratory of Zhejiang Provincial Hospital of Chinese Medicine,Hangzhou 310006,China)
出处 《中华临床感染病杂志》 CAS CSCD 2021年第1期60-65,共6页 Chinese Journal of Clinical Infectious Diseases
关键词 血流感染 碳青霉烯类 替加环素 蒙特卡洛模拟 Bloodstream infection Carbapenems Tigecycline Monte Carlo simulation
  • 相关文献

参考文献10

二级参考文献110

  • 1[14]Johnson B,Stevens T,Bouchillon S,et al.In vitro antibacterial activity of tigecyclineanovel glycylcycline against clinical isolates of Enterobacteriaceae.In:Programs and Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy,Chicago,IL,2003.Abstract 3464,p.206-207.American Society for Microbiology,Washington,DC,USA
  • 2[15]Edlund C,Nord C E.In -vitro susceptibility of anaerobic bacteria to GAR-936,a new glycylcycline.Clin Microbiol Infect 2000; 6:159-63
  • 3[16]Boucher H W,Wennersten C B,Eliopoulos G M.In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.Antimicrobial Agents and Chemotherapy 44,2225-2229
  • 4[17]Betriu C,Rodríguez-Avial I,Sánchez B A,et al.In vitro activities of tigecicline (GAR -936) against recently isolated clinical bacteria in Spain.Antimicrobial Agents and Chemotherapy,2002 ;46:892-895
  • 5[18]Petersen P J,Bradford P A,Weiss W J,et al.In vitro and in vivo activities of tigecycline (GAR-936),daptomycin,and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens.Antimicrobial Agents and Chemotherapy 46,2595-2601
  • 6[19]Cercenado E,Cercenado S,Juan A.In vitro activity of tigecycline (GAR-936),a novel glycylcycline,against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.Antimicrobial Chemothera py,2003 ;52:138-139
  • 7[20]Simona B,Pooja T,Usha K,et al.Carbapenemase-producing Klebsiella pneumoniae in Brooklyn,NY:molecular epidemiology and in vitro activity of polymyxin B and other agents.Antimicrobial Chemotherapy,2005 ;56(1):128-132
  • 8[21]Betriu C,Culebras E,Gomez M,et al.In vitro activity of tigecycline against bacteroides species.Journal of Antimicrobial Chemotherapy,2005 ;56(2):349-352
  • 9[22]Zhanel G G,Homenuik K,Nichol K,et al.The glycylcyclines:a comparative review with the tetracyclines.Drugs,2004; 64:63-88
  • 10[23]Ong T 1,Chinedum P,Nightingale H,et al Penetration,efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).Antimicrobial Chemotherapy.2005; 56 (3):498-501

共引文献511

同被引文献56

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部